Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Prezzo exec slices off 200,000 shares

Tue, 22nd Oct 2013 16:26

Kuldip Sehmi, an Executive Director at Italian restaurant chain Prezzo, on Monday traded in 200,000 shares, reducing his stake to 682,244 shares, equal to 0.29 per cent of the issued share capital. Sehmi, who is responsible for the day to day running of approximately half the Prezzo estate, sold the shares at 117p each for a total trade value of £234,000. While significant, the size of the transaction pales in comparison to that made by Jonathan Kaye, the group's Chief Executive Officer, and two of its Non-Executive Directors, last month, when they each traded in a 1.3m share slice of the company. At the beginning of September, the group posted a 17% leap in half year revenue to £79.7m, while adjusted pre-tax profit climbed 12% to £8.5m, and said it was "confident of delivering a satisfactory outcome for the year as a whole".Top Director BuysAberforth Geared Income Trust (AGIT) Director name: Mr Graham R MenziesAmount purchased: 49,865 @ 158.12p Value: £78,847JPMorgan European Inv Trust Growth Shares (JETG) Director name: Mr Andrew AdcockAmount purchased: 25,000 @ 217.50p Value: £54,375STV Group (STVG) Director name: Mr Genevieve Shore Amount purchased: 5,564 @ 264.75p Value: £14,731Top Director SellsGLOBO (GBO) Director name: Mr Gavin BurnellAmount sold: 505,000 @ 71.00p Value: £358,550Prezzo (PRZ) Director name: Mr Kuldip SehmiAmount sold: 200,000 @ 117.00p Value: £234,000GLOBO (GBO) Director name: Mr Gerasimos (Makis) BonanosAmount sold: 250,000 @ 71.00p Value: £177,500GLOBO (GBO) Director name: Mr Dimitrios GryparisAmount sold: 245,000 @ 71.00p Value: £173,950Dairy Farm International Holdings Ltd. (Singapore) (DFI) Director name: Mr Michael KokAmount sold: 13,500 @ $11.13 Value: $150,246Dillistone Group (DSG) Director name: Mr Giles Robin Fearnley Amount sold: 150,000 @ 100.10p Value: £150,150Scancell Holdings (SCLP) Director name: Dr Richard GoodfellowAmount sold: 100,000 @ 30.00p Value: £30,000Scancell Holdings (SCLP) Director name: Professor Lindy DurrantAmount sold: 100,000 @ 30.00p Value: £30,000Dunedin Enterprise Investment Trust (DNE) Director name: Mr Liz AireyAmount sold: 2,500 @ 475.00p Value: £11,875
More News
31 Oct 2022 16:46

Scancell enrols and doses first patient in latest cancer trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.

Read more
28 Oct 2022 14:42

Scancell losses widen on expense of ongoing trials

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.

Read more
28 Oct 2022 11:57

IN BRIEF: Scancell narrows annual loss as vaccine candidates progress

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.

Read more
26 Oct 2022 14:30

IN BRIEF: Scancell executive chair and co-founder both to depart

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Read more
25 Oct 2022 14:34

Scancell inks licensing deal with Nasdaq-traded Genmab

(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.

Read more
25 Oct 2022 12:17

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster.

Read more
25 Oct 2022 10:44

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
25 Oct 2022 10:03

Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Read more
23 Sep 2022 13:31

Scancell presents new, positive data on possible cancer therapies

(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.

Read more
16 Aug 2022 17:51

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.

Read more
23 Jun 2022 21:28

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
23 Jun 2022 12:38

Scancell developing 'promising' new cancer treatment approach

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

Read more
15 Jun 2022 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.

Read more
15 Jun 2022 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval.

Read more
13 Jun 2022 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.